No evidence exists to recommend a specific chemotherapy regimen in young breast cancer patients. We performed a pooled analysis of two randomised clinical trials to evaluate the efficacy of adjuvant dose-dense chemotherapy in premenopausal breast cancer patients and its impact on the risk of treatment-induced amenorrhoea.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies / Lambertini, M., Ceppi, M., Cognetti, F., Cavazzini, G., DE LAURENTIIS, M., DE PLACIDO, S., Michelotti, A., Bisagni, G., Durando, A., Valle, E., Scotto, T., De Censi, A., Turletti, A., Benasso, M., Barni, S., Montemurro, F., Puglisi, F., Levaggi, A., Giraudi, S., Bighin, C., et al.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 71:(2017), pp. 34-42-42. [10.1016/j.ejca.2016.10.030]
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
DE LAURENTIIS, MICHELINO;DE PLACIDO, SABINO;
2017
Abstract
No evidence exists to recommend a specific chemotherapy regimen in young breast cancer patients. We performed a pooled analysis of two randomised clinical trials to evaluate the efficacy of adjuvant dose-dense chemotherapy in premenopausal breast cancer patients and its impact on the risk of treatment-induced amenorrhoea.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0959804916325370-main.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
986.64 kB
Formato
Adobe PDF
|
986.64 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
